{"disease":{"id":"relapsing-forms-of-ms","name":"relapsing forms of ms"},"drugs":{"marketed":[{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04746976","title":"Study of Diroximel Fumarate in the Real-World Setting","phase":"","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04948606","title":"Exploring Diroximel Fumarate Real-world Experience in Canada and Israel","phase":"","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Biogen","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}